Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Calidi Biotherapeutics, Inc
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights
May 14, 2025
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting
April 28, 2025
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
April 25, 2025
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director
April 23, 2025
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Tickers
MTEM
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24
April 22, 2025
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors
April 17, 2025
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor
April 10, 2025
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
March 31, 2025
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights
March 31, 2025
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
March 28, 2025
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma
March 26, 2025
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform
March 10, 2025
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital
February 24, 2025
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5
January 29, 2025
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement
January 28, 2025
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025
January 13, 2025
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock
January 10, 2025
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock
January 10, 2025
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Announces Proposed Public Offering
January 08, 2025
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer
November 18, 2024
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
November 15, 2024
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock
November 14, 2024
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Announces Proposed Public Offering
November 13, 2024
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results
November 12, 2024
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences
October 24, 2024
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
October 23, 2024
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)
October 18, 2024
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma
September 30, 2024
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
August 13, 2024
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor
July 29, 2024
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.